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ABSTRACT SUMMARY 
 
The present series of test focused on evaluating the 
robustness of drug release from lipid based 
theophylline matrix tablets under a simulated fasted 
gastrointestinal passage. A robust sustained release was 
observed in all experiments. 
 
INTRODUCTION 
 
Oral extended-release (ER) dosage forms have 
represented a broad segment of research and 
development in the pharmaceutical industry for many 
years. Housing drugs with a short half-life they can 
typically enable a reduced dosing frequency which 
comes along with various potential advantages such as 
e.g. reduced fluctuations in drug levels, a reduced total 
amount of drug that has to be used, improved patient 
compliance, better and more uniform clinical effects, 
lower incidence of side effects. 
Since drug absorption from ER dosage forms is 
governed by the rate of release from the formulation 
and since these formulations typically contain much 
higher drug doses than the respective immediate-
release (IR) formulations, it is essential to assure robust 
and reproducible in vivo drug release to prevent the 
unwanted toxic peaks and sub-therapeutic troughs in 
plasma levels caused by “dose dumping” or 
insufficient/hindered drug release. 
Matrix-based formulations, consisting of the active 
drug embedded in a polymer matrix which controls 
drug release, have traditionally been the most 
commonly used ER dosage forms. Traditionally, a 
whole range of water-soluble or water-swellabe 
polymers with high molecular weight with HPMC 
being the most representative candidate have been used 
as matrix formers. However, some of these 
formulations have shown increased sensitivity to the 
composition of gastrointestinal fluids and 
gastrointestinal shear forces [1-2] which could not be 
predicted by standard dissolution experiments in the 
paddle or basket apparatus. 
To predict whether the ER dosage form meets its 
in vivo release profile goals, one needs to apply an 
adequate release test system that reflects conditions 
relevant to the in vivo conditions of drug release. 
The aim of the present set of experiments was 
evaluate the robustness of lipid based theophylline 
matrix tablets in various biorelevant dissolution test 
devices simulating passage through the human 
gastrointestinal (GI) tract. Compritol® 888 ATO 
(glyceryl dibehenate, NF), the matrix former, is a fine 
white powder composed of spherical particles with a 
mean particle diameter of 50μm. It has excellent 
tabletting properties and is chemically inert and neutral 
in flavor. With a low HLB of 1 and a high melting 
point (70°C) it has proven utility in the production of 
an insoluble and non-swellable matrix which sustains 
drug release principally by a mechanism of diffusion.  
 
EXPERIMENTAL METHODS 
 
Materials 
 
Theostat® L.P. 100 mg, lot # G00405 (Pierre Fabre 
Medicament, Boulogne, France) was obtained by 
prescription, Theophylline, Compritol® 888 ATO, 
dicalcium phosphate anhydrate (DCPA, Fujicalin®), 
lactose monohydrate, silicon dioxide (Aerosil® 200), 
Mg alumino metasilicate (Neusilin® US2) and 
magnesium stearate used for manufacturing the tablets 
as well as sodium chloride, hydrochloric acid conc., 
sodium dihydrogen phosphate, sodium hydroxide and 
acetic acid used to prepare the release media were all 
of analytical grade and purchased commercially. 
 
Tablet preparation 
 
100 mg theophylline, Compritol® 888 ATO and 
diluents were sieved through a 810 µm mesh, blended, 
subsequently lubricated and compressed using a single 
punch excenter press (14 mm, Korsch EK03). The total 
tablet weight was 600mg. 
 
Table 1: Composition of theophylline matrix tablets containing 
Compritol® 888 ATO. 
 
Ingredient   %
Theophylline  16.7 
Compritol® 888 ATO 15.0
Dicalcium phosphate anhydrate (DCPA, Fujicalin®)  42.9 
Lactose 21.4
Magnesium alumino metasilicate (Neusilin® US2)  3.0 
Magnesium stearate 1.0
Dissolution test setup 
 
Dissolution studies were performed at 37°°C with a) 
the reciprocating cylinder apparatus, (USP III; 
ERWEKA RRT 10: 200 mL per vessel, 420 µm mesh 
screens, 10 dpm), b) the flow through apparatus (USP 
IV; ERWEKA DFZ: 22.6 mm cell filled with 1 mm-
size glass beads,  Whatman® glass fiber filter (GF/F), 
tablets on holder, flow rates: stomach: 8 mL/min, small 
intestine and colon: 4 mL/min), and c) an ERWEKA 
biorelevant dissolution stress test apparatus intended to 
reflect phases of pressure waves simulating episodes of 
high gastrointestinal motility (gastric emptying (GE), 
ileocecal passage (ICP)) and phases of transport 
(780 mL, 100 rpm, 3 pressure waves (300 mbar) for 
gastric emptying and ileocecal passage, 1 min rotation 
at 100 rpm every 10 min for intestinal transport 
events). Results in USP III and IV were performed in 
the buffer media, whereas in the stress test experiments 
both buffers and the corresponding biorelevant media 
(with bile compounds) were used. Media and 
corresponding residence times are given in Table 2  
 
Table 2: Dissolution media [3] and corresponding residence 
times  
 
GI section  Medium  pH  Residence 
Stomach  SGF / FaSSGF  1.8  60 min 
Small intestine  (Blank) FaSSIF  6.8  240 min
Proximal colon  SCoF  5.8  240 min 
Colon  Blank FaSSIF  6.5  180 min
 
RESULTS AND DISCUSSION 
 
Results from the experiments simulating a fasted 
gastrointestinal passage of monolithic dosage forms 
show slight differences in the release profile which is 
most likely due to the nature of the apparatus and the 
test settings which are likely to result in different 
hydrodynamic conditions. Overall, both the Theostat® 
L.P. 100 mg marketed product and the theophylline 
Compritol® 888 ATO matrix formulation are neither 
sensitive towards the changing pH-conditions (Figures 
1-3), nor are significantly affected by biorelevant 
gastrointestinal stress conditions in the fasted GI tract 
(Figures 3 and 4).  
 
 
 
Figure 1: Theophylline release from different tablets under 
simulated fasted conditions in the reciprocating cylinder 
apparatus equipped with buffer media (mean of n = 3, ± SD) 
 
 
Figure 2: Theophylline release from different tablets under 
simulated fasted conditions in the flow through apparatus 
equipped with buffer media (mean of n = 3, ± SD) 
 
 
 
Figure 3: Theophylline release from different tablets under 
simulated fasted conditions in the biorelevant stress test 
apparatus equipped with buffer media (mean of n = 3, ± SD) 
 
 
 
Figure 4: Theophylline release from different tablets under 
simulated fasted conditions in the biorelevant stress test 
apparatus equipped with biorelevant media (mean of n = 3, ± SD) 
 
CONCLUSION 
 
Compritol® 888 matrix tablets prepared by direct 
compression offer a quite robust sustained release in 
biorelevant fasted conditions even when exposed to 
simulated mechanical stress in the fasted human GIT. 
Further studies should be carried out in fed conditions - 
which exert a significant role in drug dose dumping. 
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